Stock Markets March 3, 2026

UBS Moves Emmi to Neutral as Valuation Compresses and Capital Priorities Shift

Bank lifts price target after trimming premium multiple and flags improved capital allocation toward organic growth and ROIC

By Ajmal Hussain
UBS Moves Emmi to Neutral as Valuation Compresses and Capital Priorities Shift

UBS has upgraded Emmi AG (SIX:EMMN) from Sell to Neutral and raised its price target to CHF830 from CHF700 following a pronounced valuation de-rating and clearer capital allocation priorities. The bank adjusted 2026-2028 EPS, sales growth and margin forecasts modestly higher and said company guidance for 2026 appears achievable, supported by procurement, productivity and volume levers. Emmi is refocusing on organic growth and a 10% medium-term ROIC target while its higher-margin product mix and rising protein demand underpin near-term prospects.

Key Points

  • UBS upgraded Emmi AG (SIX:EMMN) to Neutral from Sell and raised the price target to CHF830 from CHF700.
  • Valuation multiple contracted to about 18 times P/E from a historical 22-26 times, aligning Emmi with broader food peers rather than a premium.
  • UBS increased 2026-2028 EPS estimates by 2% to 7%, raised medium-term sales growth to 2% and lifted EBITDA margin forecast to 10.75%; Emmi is guiding 1% to 3% organic sales growth in 2026 with an EBIT target of CHF335-CHF355 million.

UBS has lifted its rating on Emmi AG (SIX:EMMN) to Neutral, up from Sell, and increased its price target to CHF830 from CHF700. The Swiss bank framed the move around a significant reset in Emmi's valuation multiple and a clearer capital allocation strategy emphasizing organic growth and returns on invested capital.

According to UBS, Emmi's price-to-earnings multiple has tightened to about 18 times, down from a historical trading range of 22 to 26 times. The bank said the stock now trades more in line with broader food-sector peers, rather than carrying the premium it once did.

UBS nudged up its earnings projections for the 2026-2028 period, raising EPS estimates by between 2% and 7% to reflect improved volume dynamics and cost efficiencies. The bank also raised its medium-term assumptions: organic sales growth was increased by 25 basis points to 2%, and the forecast for the group's EBITDA margin was lifted by 25 basis points to 10.75%.

For 2026 Emmi itself is guiding organic sales growth of 1% to 3%. UBS and market consensus sit slightly higher, forecasting 2% to 3% growth, even after accounting for an almost 100 basis point headwind to sales stemming from lower dairy prices.

On profitability, Emmi's 2026 EBIT target is CHF335 million to CHF355 million. UBS's internal projection is CHF352 million, compared with a consensus view of CHF349 million. UBS described the guidance as achievable, pointing to centralized procurement, productivity initiatives and volume growth as supporting factors.

Importantly for investors focused on capital allocation, UBS highlighted Emmi's explicit pivot away from mergers and acquisitions toward organic sales growth and returns metrics over the next two to three years. The company has introduced a medium-term return on invested capital target of 10%.

Volume momentum remains a key underpin. UBS noted Emmi has recently delivered solid year-over-year volume growth in the range of 2% to 3%. The bank attributed this to Emmi's concentrated exposure to higher-margin dairy segments - specifically premium cheese, chilled Caffe Latte and Italian dessert categories - which collectively represent roughly 40% of group sales.

Looking to the first half of 2026, UBS expects Emmi to show tangible earnings and margin progression against easier year-on-year comparisons. The firm is projecting organic sales growth above 2% and an improvement in EBIT margin of at least 10 to 20 basis points year-on-year for that period.

UBS also pointed to shifting consumer protein trends as a tailwind for Emmi's product mix. The bank cited data showing that around 23% of Americans now follow high-protein diets, up from 4% in 2018, suggesting stronger demand for protein-rich dairy items may support the group's higher-margin categories.


Context for investors

This re-rating from UBS centers on valuation normalisation and a capital allocation timetable that prioritizes organic growth and a measurable ROIC objective. For market participants and sector analysts, the update adjusts expectations on Emmi's earnings trajectory and repositions the stock relative to food-sector peers.

Risks

  • Lower dairy prices are expected to create nearly a 100 basis point negative impact on sales for 2026, weighing on revenue growth in the consumer staples and dairy sectors.
  • Achievement of Emmi's guidance depends on successful execution of centralized procurement, productivity improvements and volume growth - operational execution risks in manufacturing and supply chain could affect outcomes.
  • The company's shift from acquisitions to organic growth and a 10% ROIC target introduces execution risk over the next two to three years if organic initiatives or return targets prove harder to deliver than forecast.

More from Stock Markets

Bank of Ireland Unveils €530m Share Buyback as Government Moves to Reappoint Central Bank Governor Mar 3, 2026 Hormuz Closure Enters Fourth Day as Tankers Reportedly Struck Mar 3, 2026 Viper Energy Stock Drops After $798M Secondary Share Sale by Parent and Affiliates Mar 3, 2026 Target Raises 2026 Sales Outlook; Shares Jump in Premarket Mar 3, 2026 Infosys and Intel Broaden Collaboration to Move AI From Pilot to Production Mar 3, 2026